Alto Neuroscience, Inc. (ANRO) vs Rigel Pharmaceuticals, Inc. (RIGL)
- Alto Neuroscience, Inc. ANRO 22.07 −2.43%
- Rigel Pharmaceuticals, Inc. RIGL 45.97 −2.71%
Alto Neuroscience, Inc. and Rigel Pharmaceuticals, Inc. are both Biotechnology companies. Alto Neuroscience, Inc. and Rigel Pharmaceuticals, Inc. are of similar size ($887.7M and $882.6M). Alto Neuroscience, Inc. has negative trailing earnings, so its P/E is not meaningful; Rigel Pharmaceuticals, Inc. trades at 2.6×. Rigel Pharmaceuticals, Inc. has the higher net margin (116.3% vs 0.00%) and the higher return on invested capital (16.5% vs 0.00%). Across the 13 metrics below, Rigel Pharmaceuticals, Inc. leads on 12 and Alto Neuroscience, Inc. on 1.
Valuation
Profitability
| Metric | ANRO | RIGL | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 91.39% | 65.16% |
| Operating margin | 0.00% | 31.45% | 0.00% |
| Net margin | 0.00% | 116.30% | 0.00% |
| Free cash flow margin | 0.00% | 3.19% | 0.00% |
| Return on equity | (49.17%) | 126.90% | (56.36%) |
| Return on assets | (40.90%) | 88.46% | (48.04%) |
| Return on invested capital | 0.00% | 16.48% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack